GGHC
AMLX icon

Gilder Gagnon Howe & Co’s Amylyx Pharmaceuticals AMLX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-688,438
Closed -$12.6M – 251
2023
Q3 		$12.6M Buy
+688,438
New +$14.6M 0.19% 98

Other funds holding AMLX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gilder Gagnon Howe & Co's AMLX Position: Q4 2023 in Review

Gilder Gagnon Howe & Co sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2023, closing a stake of 688,438 shares — an estimated $12.6M sold.

Gilder Gagnon Howe & Co first reported a position in AMLX in Q3 2023 and held it in 1 quarter. The position peaked at $12.6M in Q3 2023. 178 funds tracked by Wall St. Rank hold AMLX as of Q4 2023.

  • Gilder Gagnon Howe & Co reported no remaining Amylyx Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 688,438 Amylyx Pharmaceuticals shares in Q4 2023, an estimated $12.6M.
  • Gilder Gagnon Howe & Co first reported a position in Amylyx Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Amylyx Pharmaceuticals position peaked at $12.6M in Q3 2023.
  • 178 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2023.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2023, filed 14 Feb 2024.